Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zoledronic acid.

S M Cheer1, S Noble

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 12, 2001
PubMed
Summary
This summary is machine-generated.

Zoledronic acid, a potent bisphosphonate, effectively treats hypercalcaemia of malignancy. It normalizes serum calcium levels and offers a longer duration of response compared to pamidronic acid.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Oncology
  • Endocrinology

Background:

  • Zoledronic acid is a novel bisphosphonate agent.
  • Bisphosphonates are known to inhibit osteoclast bone resorption.
  • Hypercalcaemia of malignancy is a serious complication requiring effective treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of zoledronic acid in treating hypercalcaemia of malignancy.
  • To compare zoledronic acid with pamidronic acid for normalizing serum calcium levels.
  • To assess the duration of response and time to relapse after treatment.

Main Methods:

  • Pooled analysis of two randomized, double-blind, parallel-group trials.
  • Comparison of single intravenous infusions of zoledronic acid (4 or 8 mg) versus pamidronic acid (90 mg).

Related Experiment Videos

  • Assessment of serum calcium levels, time to relapse, and adverse events.

    • Main Results:

    • Zoledronic acid (4 or 8 mg IV) was significantly more effective than pamidronic acid (90 mg IV) in normalizing serum calcium.
    • Zoledronic acid treatment resulted in a significantly longer median time to relapse.
    • No significant differences in tolerability were observed between zoledronic acid and pamidronic acid.

    Conclusions:

    • Zoledronic acid is a highly effective treatment for hypercalcaemia of malignancy.
    • Its rapid administration and prolonged efficacy make it a valuable therapeutic option.
    • Common adverse events include fever, anemia, nausea, constipation, and dyspnea.